Source comparison
BPC-157 Research Hormonal Health Comparison: Growth Factor vs Direct Hormone Modulation
Primary Target VEGF, IGF-1, TGF-beta expression in injured tissue Specific hormone receptors (androgen receptor, thyroid receptor) None for BPC-157 in controlled trials; extensive for hormone agonists BPC-157's indirect mechanism reduces predictable endocrine
This comparison does not assign a generated winner or score.
- Primary Target
- VEGF, IGF-1, TGF-beta expression in injured tissue
- Specific hormone receptors (androgen receptor, thyroid receptor)
- None for BPC-157 in controlled trials; extensive for hormone agonists
- BPC-157's indirect mechanism reduces predictable endocrine risk but creates uncertainty. Hormone agonists have known side-effect profiles
- Systemic Hormone Alteration
- No evidence of altered baseline testosterone, estrogen, cortisol, or thyroid hormone levels in animal models
- Direct dose-dependent elevation of target hormone and downstream metabolites
- Animal studies show no TSH, T4, or sex hormone changes; no human validation
- Absence of systemic hormone changes in rodents suggests lower endocrine disruption risk, but species differences and dosing gaps limit confidence
- Angiogenesis and Tissue Vascularisation
- Documented VEGF upregulation (up to 340% in tendon models); vascular effects on reproductive/thyroid tissue unexplored
- Testosterone increases hematocrit via erythropoiesis; thyroid hormone affects metabolic rate but not angiogenesis
- VEGF changes documented in preclinical models only; no human vascular imaging or endocrine correlation studies
- VEGF's role in hormone-sensitive tissues (ovaries, prostate, thyroid) creates theoretical risk that's neither confirmed nor ruled out
- Reproductive Health Impact
- Mechanistic plausibility via VEGF (endometrial angiogenesis, ovarian function) but zero fertility or menstrual data
- Testosterone suppresses spermatogenesis via HPG axis feedback; exogenous estrogen alters menstrual cycle
- No human data on menstrual regularity, sperm parameters, or ovulation markers during BPC-157 use
- The data gap is the risk. Researchers can't counsel participants on reproductive outcomes without baseline and post-treatment hormone panels
- Metabolic and Insulin Sensitivity
- Possible IGF-1 receptor sensitisation in muscle; glucose metabolism effects unstudied
- Growth hormone and IGF-1 analogs alter insulin sensitivity; thyroid hormone increases basal metabolic rate
- No HbA1c, fasting insulin, or HOMA-IR data in BPC-157 trials
- IGF-1 pathway involvement warrants metabolic monitoring, especially in diabetic or prediabetic populations. This is a design oversight, not a known contraindication